Combination of modified SHIRPA and pharmacological approach uncovers neuronal alteration in senescence-accelerated mouse prone 6 (SAMP6) strain

Neuroscience Letters

Volumn 458, Issue 2, 2009, Pages 53-56

  Niimi, Kimie ^a,b   Takahashi, Eiki ^b  

^a Brain Science And Life Technology Research Foundation   (Japan)

^b RIKEN BRAIN SCIENCE INSTITUTE   (Japan)

Author keywords

Apomorphine; Dopamine; Locomotor activity; SAMP6; SHIRPA

Indexed keywords

APOMORPHINE; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT;

AGING; AKR/J STRAIN; ANIMAL MODEL; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG DOSE INCREASE; EXPERIMENTAL MODEL; EXPERIMENTAL MOUSE; GENE TARGETING; LOCOMOTION; MOUSE; MOUSE STRAIN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REARING; SENESCENCE ACCELERATED MOUSE; SENESCENCE ACCELERATED MOUSE PRONE 6; SENESCENCE ACCELERATED MOUSE RESISTANT 1; SENILE OSTEOPOROSIS; SIGNAL TRANSDUCTION; TASK PERFORMANCE; TRANSGENIC MOUSE;

ANIMALS; APOMORPHINE; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; EXPLORATORY BEHAVIOR; HINDLIMB SUSPENSION; MOTOR ACTIVITY; NEURONS; OSTEOPOROSIS; PHENOTYPE; RABBITS; RECEPTORS, DOPAMINE;

EID: 65149096425     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2009.04.042     Document Type: Article

References (37)

1. Arrequi A., Azpiroz A., Brain P.F., and Simon V. Effects of two selective dopaminergic antagonists on ethologically-assessed encounters in male mice. Gen. Pharmacol. 24 (1993) 353-356
2. Barik J.H., Picetti R., Saiardi A., Thiriet G., Dierich A., Depaulis A., Le Meur M., and Borrelli E. Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors. Nature 377 (1995) 424-428
3. Breese G.R., Duncan G.E., Napier T.C., Bondy S.C., Iorio L.C., and Mueller R.A. 6-Hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding. J. Pharmacol. Exp. Ther. 240 (1987) 167-176
4. Clifford J.J., Tighe O., Croke D.T., Sibley D.R., Drago J., and Waddington J.L. Topographical evaluation of the phenotype of spontaneous behaviour in mice with targeted gene deletion of the D1A dopamine receptor: paradoxical elevation of grooming syntax. Neuropharmacology 37 (1998) 1595-1602
5. Clifford J.J., Usiello A., Vallone S., Kinsella A., Borrelli E., and Waddington J.L. Topographical evaluation of behavioural phenotype in a line of mice with targeted gene deletion of the D2 dopamine receptor. Neuropharmacology 39 (2000) 382-390
6. Deleu D., Hanssens Y., and Northway M.G. Subcutaneous apomorphine: an evidence-based review of its use in Parkinson's disease. Drugs Aging 21 (2004) 687-709
7. Drago J., Gerfen C.R., Lachowicz J.E., Steiner H., Hollon T.R., Love P.E., Ooi G.T., Grinberg S., Lee E.J., Huang S.P., Barlett P.F., Jose P.A., Sibley D.R., and Westphal H. Altered striatal function in a mutant mouse lacking D1A dopamine receptors. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 12564-12568
8. Dulawa S.C., Gramdv D.K., Low M.J., Paulus M.P., and Gever M.A. Dopamine D4 receptor-knock-out mice exhibit reduced exploration of novel stimuli. J. Neurosci. 19 (1999) 9550-9556
9. Fetsko L.A., Xu R., and Wang Y. Alterations in D1/D2 synergism may account for enhanced stereotypy and reduced climbing in mice lacking dopamine D2L receptor. Brain Res. 967 (2003) 191-200
10. Griffin W.S.T., Sheng J.G., and Mrak R.E. Senescence-accelerated overexpression of S100β in brain of SAMP6 mice. Neurobiol. Aging 19 (1998) 71-76
11. Gupta M.L., Nath R., Gupta T.K., and Gupta G.P. A study of central neurotransmitter mechanisms in morphine-induced 'Straub reaction' in mice: role of central dopamine receptors. Clin. Exp. Pharmacol. Physiol. 15 (1988) 727-732
12. Hagell P., and Odin P. Apomorphine in the treatment of Parkinson's disease. J. Neurosci. Nurs. 33 (2001) 21-34, 37-38
13. Halberda J.P., Middaugh L.D., Gard B.E., and Jackson B.P. DAD1- and DAD2-like agonist effect on motor activity of C57 mice: difference compared to rats. Synapse 26 (1997) 81-92
14. Hasegawa Y., Kurachi M., and Otomo S. Dopamine D2 receptors and spinal cord excitation in mice. Eur. J. Pharmacol. 184 (1990) 207-212
15. Henderson N.D., Turri M.G., DeFries J.C., and Flint J. QTL analysis of multiple behavioral measures of anxiety in mice. Behav. Genet. 34 (2004) 267-293
16. Hiroi N., Martin A.B., Grande C., Alberti I., Rivera A., and Moratalla R. Molecular dissection of dopamine receptor signaling. J. Chem. Neuroanat. 23 (2003) 237-242
17. Kitanaka N., Kitanaka J., and Takemura M. Behavioral sensitization and alteration in monoamine metabolism in mice after single versus repeated methamphetamine administration. Eur. J. Pharmacol. 474 (2003) 63-70
18. Kuczenski R., Segal D.S., Cho A.K., and Melega W. Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine. J. Neurosci. 15 (1995) 1308-1317
19. Kula N.S., Baldessarini R.J., Bromley S., and Neumeyer J.L. Effects of isomers of apomorphines on dopamine receptors in striatal and limbic tissue of rat brain. Life Sci. 37 (1985) 1051-1057
20. van Laar T. Levodopa-induced response fluctuations in patients with Parkinson's disease: strategies for management. CNS Drugs 17 (2003) 475-489
21. Laprada N., Radja F., Reader T.A., and Soghomonian J.J. Dopamine receptor agonists regulate levels of the serotonin 5-HT2A receptor and its mRNA in a subpopulation of rat striatal neurons. J. Neurosci. 16 (1996) 3727-3736
22. Masuya H., Inoue M., Wada Y., Shimizu A., Nagano J., Kawai A., Inoue A., Kagami T., Hirayama T., Yamaga A., Kaneda H., Kobayashi K., Minowa O., Miura I., Gondo Y., Noda T., Wakana S., and Shiroishi T. Implementation of the modified-SHIRPA protocol for screening of dominant phenotypes in a large-scale ENU mutagenesis program. Mamm. Genome 16 (2005) 829-837
23. Matsushita M., Tsuboyama T., Kasai R., Okumura H., Yamamuro T., Higuchi K., Higuchi K., Kohno A., Yonezu T., Utani A., Umezawa M., and Takeda T. Age-related changes in bone mass in the senescence-accelerated mouse (SAM). Am. J. Pathol. 125 (1986) 276-283
24. McNamara F.N., Clifford J.J., Tighe O., Kinsella A., Drago J., Croke D.T., and Waddington J.L. Congenic D1A dopamine receptor mutants: ethologically based resolution of behavioral topography indicates genetic background as a determinant of knockout phenotype. Neuropsychopharmacology 28 (2003) 86-99
25. Milner L.C., and Crabbe J.C. Three murine anxiety models: results from multiple inbred strain comparisons. Genes Brain Behav. 7 (2008) 496-505
26. Muguet D., Broussolle E., and Chazot G. Apomorphine in patients with Parkinson's disease. Biomed. Pharmacother. 49 (1995) 197-209
27. Nakamura K., Kikusui T., Takeuchi Y., and Mori Y. The influence of early weaning on aggressive behavior in mice. J. Vet. Med. Sci. 65 (2003) 1347-1349
28. Nishikawa T., Mataga N., Takashima M., and Toru M. Behavioral sensitization and relative hyperresponsiveness of striatal and limbic dopaminergic neurons after repeated methamphetamine treatment. Eur. J. Pharmacol. 88 (1983) 195-203
29. Rodriguez-Arias M., Minarro J., Aquilar M.A., Pinazo J., and Simon V.M. Effects of risperidone and SCH 23390 on isolation-induced aggression in male mice. Eur. Neuropsychopharmacol. 8 (1998) 95-103
30. Rogers D.C., Fisher E.M.C., Brown S.D.M., Perters J., Hunter A.J., and Martin J.E. Behavioral and functional analysis of mouse phenotype: SHIRPA, a proposed protocol for comprehensive phenotype assessment. Mamm. Genome 8 (1997) 711-713
31. Russell K.H., Hagenmeyer-Houser S.H., and Sanberg P.R. Haloperidol-induced emotional defection: a possible model for neuroleptic anxiety syndrome. Psychopharmacology 91 (1987) 45-49
32. Takeda T., Hosokawa M., and Higuchi K. Senescence-accelerated mouse (SAM): a novel murine model of senescence. Exp. Gerontol. 32 (1997) 105-109
33. Takeda T. Senescence-accelerated mouse (SAM): a biogerontological resource in aging research. Neurobiol. Aging 20 (1999) 105-110
34. Tran A.H., Tamura R., Uwano T., Kobayashi T., Katsuyashi T., Katsuki M., and Ono T. Dopamine D1 receptors involved in locomotor activity and accumbens neural responses to prediction of reward associated with place. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 2117-2122
35. Wang Y., Xu R., Sasaoka T., Tonegawa S., Kung M.P., and Sankoorikal E.B. Dopamine D2 long receptor-deficient mice display alterations in striatum-dependent functions. J. Neurosci. 20 (2000) 8305-8314
36. Young K.A., Zavodny R., and Hicks P.B. Effects of serotonergic agents on apomorphine-induced locomotor activity. Psychopharmacology 110 (1993) 97-102
37. Zarrindast M.R., Bayat A., and Shafaghi B. Involvement of dopaminergic receptor subtypes in straub tail behaviour in mice. Gen. Pharmacol. 24 (1993) 127-130